We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
+8.75%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$44.9M
AUM Growth
-$9.95M
(-18%)
Cap. Flow
-$12.6M
Cap. Flow
% of AUM
-28.07%
Top 10 Holdings %
Top 10 Hldgs %
83.47%
Holding
31
New
4
Increased
3
Reduced
8
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven
BHVN
|
+$1.38M |
| 2 |
BLUE
bluebird bio
BLUE
|
+$748K |
| 3 |
Disc Medicine
IRON
|
+$362K |
| 4 |
Benitec Biopharma
BNTC
|
+$349K |
| 5 |
Arcutis Biotherapeutics
ARQT
|
+$346K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ardelyx
ARDX
|
+$2.87M |
| 2 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$1.98M |
| 3 |
Insmed
INSM
|
+$1.34M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$1.15M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$1.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.66% |
| 2 | Technology | 0.1% |
| 3 | Communication Services | 0.04% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares Russell 2000 ETF
IWM
$81.6B
| $18.2M | 40.58% |
82,500
| – | – |
|
|
2
Insmed
INSM
$23.1B
| $3.81M | 8.49% |
52,200
-18,135
| -26% | -$1.34M |
|
3
Geron
GERN
$924M
| $2.86M | 6.37% |
630,000
| – | – |
|
|
4
Ardelyx
ARDX
$1.25B
| $2.55M | 5.68% |
370,000
-486,667
| -57% | -$2.87M |
|
5
Milestone Pharmaceuticals
MIST
$148M
| $2.51M | 5.6% |
1,654,154
-686,053
| -29% | -$998K |
|
|
6
Biohaven
BHVN
$2.14B
| $1.77M | 3.94% |
+35,400
| New | +$1.38M |
|
7
PUT
Mirum Pharmaceuticals
MIRM
$6.86B
| $1.75M | 3.91% |
45,000
| – | – |
|
|
8
Kiniksa Pharmaceuticals
KNSA
$4.85B
| $1.53M | 3.42% |
61,400
-43,291
| -41% | -$1.05M |
|
9
BridgeBio Pharma
BBIO
$16.7B
| $1.25M | 2.78% |
49,000
| – | – |
|
|
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.22M | 2.72% |
693,778
-1,421,049
| -67% | -$1.98M |
|
11
Fennec Pharmaceuticals
FENC
$355M
| $1.07M | 2.39% |
215,000
+45,000
| +26% | +$260K |
|
12
Mineralys Therapeutics
MLYS
$2.38B
| $957K | 2.13% |
79,000
| – | – |
|
13
Syndax Pharmaceuticals
SNDX
$1.83B
| $889K | 1.98% |
46,200
-18,800
| -29% | -$388K |
|
|
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
| $839K | 1.87% |
64,000
-18,500
| -22% | -$282K |
|
|
BLUE
15
DELISTED
bluebird bio
BLUE
| $820K | 1.83% |
78,913
+45,000
| +133% | +$748K |
|
16
Regenxbio
RGNX
$628M
| $606K | 1.35% |
57,750
+21,500
| +59% | +$262K |
|
17
Jasper Therapeutics
JSPR
$24M
| $602K | 1.34% |
32,000
| – | – |
|
|
18
Disc Medicine
IRON
$2.88B
| $378K | 0.84% |
+7,700
| New | +$362K |
|
|
19
Benitec Biopharma
BNTC
$401M
| $358K | 0.8% |
+39,000
| New | +$349K |
|
|
20
Arcutis Biotherapeutics
ARQT
$3.43B
| $326K | 0.73% |
+35,100
| New | +$346K |
|
21
Seres Therapeutics
MCRB
$49.7M
| $322K | 0.72% |
17,038
| – | – |
|
|
LUMO
22
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $153K | 0.34% |
39,589
-51,205
| -56% | -$142K |
|
23
Microsoft
MSFT
$2.86T
| $43K | 0.1% |
100
| – | – |
|
|
SPRB
24
Spruce Biosciences
SPRB
$119M
| $35.6K | 0.08% |
1,000
| – | – |
|
25
Alphabet (Google) Class C
GOOG
$3.91T
| $16.7K | 0.04% |
100
| – | – |
|
Similar funds
PA
PA
SR
SCTC
SRA
CP
B
CVV
Lion Point Capital's Q3 2024 Portfolio in Review
As of Q3 2024, Lion Point Capital held 31 positions worth $44.9M, down 18% from $54.9M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Lion Point Capital withdrew a net $12.6M in Q3 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $1.15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 51% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Lion Point Capital opened a new position in Biohaven worth $1.77M.
- Lion Point Capital's largest Q3 2024 buy was Biohaven: 35,400 shares worth $1.77M.
- Lion Point Capital added most to bluebird bio in Q3 2024, an estimated $748K increase.
- Lion Point Capital's biggest Q3 2024 reduction was Ardelyx, cutting an estimated $2.87M.
- Lion Point Capital fully exited Neurocrine Biosciences in Q3 2024, selling an estimated $1.15M.
- Lion Point Capital's ten largest holdings make up 83% of its $44.9M portfolio in Q3 2024.
- Lion Point Capital opened 4 new positions and closed 6 in Q3 2024.
- Lion Point Capital's portfolio value fell 18% quarter-over-quarter to $44.9M.
Based on Lion Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.